Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients

Seoul National University Hospital112 enrolled

Overview

Serum antibody titre against COVID-19 spike protein will be measured before, after the first dose, and after the second dose (when applicable) in cancer patients who are receiving or received anti-cancer drugs. Side effects of vaccination and actual incidence of COVID-19 will be monitored.

Study Type

OBSERVATIONAL

Enrollment

112

Conditions

Cancer Covid19

Interventions

COVID-19 vaccineDRUG

Subjects will be vaccinated with COVID-19 vaccines approved in Korea. Data on specific vaccines will be gathered.

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 20 years of age or older * Patients who are receiving or received anti-cancer drugs * Those who are not vaccinated against COVID-19 at the time of enrollment * Written informed consent Exclusion Criteria: * Any contraindications to COVID-19 vaccines * Those who were already vaccinated * Those who are on immunosuppressants or infected with HIV * Those who underwent organ transplantation * Active infections (for example, pneumonia)

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Antibody titre after vaccination

Antibody titre as measured by Anti-SARS-CoV-2 ELISA (IgG)

Time frame: 21-28 days after completion of vaccination

Secondary Outcomes

Antibody titer according to chemotherapy cycle, side effects, and use of corticosteroids or antipyretics

Antibody titre as measured by Anti-SARS-CoV-2 ELISA (IgG)

Time frame: 21-28 days after completion of vaccination

Incidence of COVID-19 infection

Incidence of actual COVID-19 infection

Time frame: 6 months after completion of vaccination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.